Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium
Publication
, Conference
O'Donnell, J; Buckingham, L; Hao, T; Secord, AA; Zhou, C; Bae-Jump, V
Published in: GYNECOLOGIC ONCOLOGY
2021
Duke Scholars
Published In
GYNECOLOGIC ONCOLOGY
EISSN
1095-6859
ISSN
0090-8258
Publication Date
2021
Volume
162
Start / End Page
S41 / S42
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Donnell, J., Buckingham, L., Hao, T., Secord, A. A., Zhou, C., & Bae-Jump, V. (2021). Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium. In GYNECOLOGIC ONCOLOGY (Vol. 162, pp. S41–S42).
O’Donnell, Jillian, Lindsey Buckingham, Tianran Hao, Angeles Alvarez Secord, Chunxiao Zhou, and Victoria Bae-Jump. “Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium.” In GYNECOLOGIC ONCOLOGY, 162:S41–42, 2021.
O’Donnell J, Buckingham L, Hao T, Secord AA, Zhou C, Bae-Jump V. Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium. In: GYNECOLOGIC ONCOLOGY. 2021. p. S41–2.
O’Donnell, Jillian, et al. “Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium.” GYNECOLOGIC ONCOLOGY, vol. 162, 2021, pp. S41–42.
O’Donnell J, Buckingham L, Hao T, Secord AA, Zhou C, Bae-Jump V. Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium. GYNECOLOGIC ONCOLOGY. 2021. p. S41–S42.
Published In
GYNECOLOGIC ONCOLOGY
EISSN
1095-6859
ISSN
0090-8258
Publication Date
2021
Volume
162
Start / End Page
S41 / S42
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis